Company Filing History:
Years Active: 2018
Title: The Innovations of Rulei Chen
Introduction
Rulei Chen is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. His work focuses on addressing critical health issues such as type II diabetes and obesity.
Latest Patents
Rulei Chen holds a patent for a long-acting blood sugar decreasing fusion protein. This innovative invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section. The preparation method and purpose of this fusion protein are noteworthy, as it retains the biological activity of GLP-1 while significantly prolonging its half-life in vivo. This fusion protein can be utilized to treat type II diabetes, obesity, and other diseases by decreasing serum glucose, suppressing gastrointestinal motility, and regulating food intake.
Career Highlights
Rulei Chen is currently employed at Genor Biopharma Co., Ltd., where he continues to advance his research and development efforts. His expertise in recombinant protein technology has positioned him as a key player in the biotechnology sector.
Collaborations
Some of his notable coworkers include Joe Zhou and Qing Zhou, who contribute to the collaborative environment at Genor Biopharma Co., Ltd. Their combined efforts enhance the innovative capabilities of the company.
Conclusion
Rulei Chen's contributions to biotechnology, particularly through his patented fusion protein, demonstrate his commitment to improving health outcomes for individuals with diabetes and obesity. His work exemplifies the impact of innovation in the medical field.